Startups
TIBEAY BioSciences
TIBEAY BioSciences is a Netherlands-based clinical-stage biotechnology company developing an investigational treatment for acute traumatic brain injury. Its lead small molecule, ronopterin, is designed to inhibit inducible nitric oxide synthase and reduce secondary neurological damage after the initial trauma. The company is preparing a European multicenter Phase 3b study in patients with severe traumatic brain injury, alongside manufacturing and regulatory work needed for a potential European marketing application. The medicine is in clinical development and is not an approved treatment. The financing issuer is TIBEAY Biosciences B.V., based in Nijmegen.